David E. Zembower - Concepedia

Concepedia

Author

David E. Zembower

Also Known As

A.B. Burgin Jr., D E Zembower, D. E. ZEMBOWER, D. ZEMBOWER, D. Zembower, DAVID E. ZEMBOWER, David E Zembower, David E. Zembower, David Zembower

40

Publications

1.4K

Citations

18

H-Index

48

Concepts

All Affiliations

Mayo Clinic deCODE Genetics (Iceland)Woodside (Australia)Southern Research Institute Georgetown University

DE

About

David E. Zembower is an author at Mayo Clinic specializing in medicinal chemistry, natural sciences, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	11	11	344
2	Medicine	9	9	321
3	Biochemistry	9	9	293
4	Biomolecular Engineering	4	4	89
5	Engineering	3	3	52

David E. Zembower

×

21

Publications

1.4K

Citations

18

H-Index

	Year	Citations
Structures of Three Classes of Anticancer Agents Bound to the Human Topoisomerase I−DNA Covalent Complex Bart L. Staker, M.D. Feese, Mark Cushman, Journal of Medicinal Chemistry	2005	527
Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography D.R. Davies, B. Mamat, Ólafur Þ. Magnússon, Journal of Medicinal Chemistry	2009	119
Total Synthesis of Robustaflavone, a Potential Anti-Hepatitis B Agent David E. Zembower, Heping Zhang The Journal of Organic Chemistry	1998	76
Structural Analogues of the Calanolide Anti-HIV Agents. Modification of the <i>trans</i>-10,11-Dimethyldihydropyran-12-ol Ring (Ring C) David E. Zembower, Shuyuan Liao, Michael T. Flavin, Journal of Medicinal Chemistry	1997	69
Antagonists of the EP<sub>3</sub> Receptor for Prostaglandin E<sub>2</sub> Are Novel Antiplatelet Agents That Do Not Prolong Bleeding Jasbir Singh, Wayne E. Zeller, Nian Zhou, ACS Chemical Biology	2009	69
Robustaflavone, a potential non-nucleoside anti-hepatitis B agent David E. Zembower, Yuh‐Meei Lin, Michael T. Flavin, Antiviral Research	1998	64
Discovery of 4-[(2<i>S</i>)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic Acid (DG-051) as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 Biosynthesis Vincent Sandanayaka, B. Mamat, Rama K. Mishra, Journal of Medicinal Chemistry Ligand EfficiencyChemical BiologyPharmaceutical ChemistrySystems PharmacologyMolecular Pharmacology	2009	63
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI Ze‐Qi Xu, Robert W. Buckheit, Tracy L. Stup, Bioorganic & Medicinal Chemistry Letters 12-Oxocalanolide AMedicinal ChemistryPharmaceutical ScienceDerivative (Chemistry)Biochemistry	1998	44
Structure−Activity Relationship Studies Leading to the Identification of (2<i>E</i>)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-l<i>H</i>-indol-7-yl]-<i>N</i>-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding Jasbir Singh, Wayne E. Zeller, Nian Zhou, Journal of Medicinal Chemistry PharmacotherapyLead Compound 50Prolong BleedingThrombosisMedicinal Chemistry	2009	41
Development of a Scalable Process for DG-041, a Potent EP<sub>3</sub> Receptor Antagonist, via Tandem Heck Reactions Siead Zegar, Christopher J. Tokar, Livia A. Enache, Organic Process Research & Development Molecular BiologyPharmaceutical ChemistrySmall MoleculesMolecular PharmacologyMedicinal Chemistry	2007	37

Page 1